These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16504409)

  • 1. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain.
    Melrose H; Lincoln S; Tyndall G; Dickson D; Farrer M
    Neuroscience; 2006; 139(3):791-4. PubMed ID: 16504409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain.
    Higashi S; Moore DJ; Colebrooke RE; Biskup S; Dawson VL; Arai H; Dawson TM; Emson PC
    J Neurochem; 2007 Jan; 100(2):368-81. PubMed ID: 17101029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 expression linked to dopamine-innervated areas.
    Galter D; Westerlund M; Carmine A; Lindqvist E; Sydow O; Olson L
    Ann Neurol; 2006 Apr; 59(4):714-9. PubMed ID: 16532471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain.
    Simón-Sánchez J; Herranz-Pérez V; Olucha-Bordonau F; Pérez-Tur J
    Eur J Neurosci; 2006 Feb; 23(3):659-66. PubMed ID: 16487147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of PINK1 and LRRK2 in rat and mouse brain.
    Taymans JM; Van den Haute C; Baekelandt V
    J Neurochem; 2006 Aug; 98(3):951-61. PubMed ID: 16771836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
    Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
    J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease.
    Westerlund M; Belin AC; Anvret A; Bickford P; Olson L; Galter D
    Neuroscience; 2008 Mar; 152(2):429-36. PubMed ID: 18272292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra.
    Han BS; Iacovitti L; Katano T; Hattori N; Seol W; Kim KS
    Neurosci Lett; 2008 Sep; 442(3):190-4. PubMed ID: 18634852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.
    Higashi S; Biskup S; West AB; Trinkaus D; Dawson VL; Faull RL; Waldvogel HJ; Arai H; Dawson TM; Moore DJ; Emson PC
    Brain Res; 2007 Jun; 1155():208-19. PubMed ID: 17512502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
    Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
    Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
    Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
    Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    Gillardon F
    J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.
    Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F
    Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.
    Melrose HL; Kent CB; Taylor JP; Dachsel JC; Hinkle KM; Lincoln SJ; Mok SS; Culvenor JG; Masters CL; Tyndall GM; Bass DI; Ahmed Z; Andorfer CA; Ross OA; Wszolek ZK; Delldonne A; Dickson DW; Farrer MJ
    Neuroscience; 2007 Jul; 147(4):1047-58. PubMed ID: 17611037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
    Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
    Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.
    Melrose HL; Dächsel JC; Behrouz B; Lincoln SJ; Yue M; Hinkle KM; Kent CB; Korvatska E; Taylor JP; Witten L; Liang YQ; Beevers JE; Boules M; Dugger BN; Serna VA; Gaukhman A; Yu X; Castanedes-Casey M; Braithwaite AT; Ogholikhan S; Yu N; Bass D; Tyndall G; Schellenberg GD; Dickson DW; Janus C; Farrer MJ
    Neurobiol Dis; 2010 Dec; 40(3):503-17. PubMed ID: 20659558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
    Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
    Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.